UroGen surges on Q4 beat, ZUSDURI launch momentum
Biotech beats earnings expectations by 20.9% as bladder cancer treatments drive growth
UroGen Pharma shares climbed in early trading Monday after the biotechnology company reported fourth-quarter results that topped analyst expectations, driven by strong performance from its bladder cancer treatments and progress on a promising clinical candidate.
The company posted revenue of $37.8 million for the fourth quarter of 2025, exceeding the consensus estimate of $32.5 million by 16.5%. Its loss per share narrowed to $0.54, better than the projected loss of $0.68 and representing a 20.9% beat on the bottom line, according to the company's earnings announcement.
JELMYTO, the company's treatment for low-grade upper tract urothelial cancer, generated $94 million in sales for full-year 2025, growing 7% year-over-year on underlying demand. UroGen provided 2026 guidance of $97 million to $101 million for the product, representing roughly 3% to 7% growth above 2025 levels.
The bigger story may be ZUSDURI, UroGen's newly launched treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The drug achieved $15.8 million in sales during 2025 following its June 2025 approval, with a permanent J Code taking effect January 1, 2026 to improve reimbursement and patient access. Chief Executive Officer Liz Barrett has called ZUSDURI a "potential greater than $1 billion peak sales opportunity."
On the clinical development front, UroGen reported encouraging interim data from its Phase 3 UTOPIA trial for UGN-103, an investigational therapy for the same bladder cancer indication. The treatment demonstrated a 77.8% complete response rate at three months, supporting a planned New Drug Application submission in the second half of 2026. Analysts at H.C. Wainwright and Needham have previously highlighted UGN-103 as a key catalyst, noting the significant unmet need in non-muscle invasive bladder cancer.
In a separate announcement Monday, UroGen revealed it had refinanced $200 million of debt with Pharmakon Advisors at a fixed 8.25% interest rate, replacing an existing $125 million facility. The refinancing extends the amortization period to quarterly payments beginning in the first quarter of 2030 and provides additional non-dilutive capital. The company also secured an option to draw an additional $50 million before June 30, 2027.
The dual announcements come as UroGen works to build its commercial footprint in urological oncology. The company's reverse thermal gel platform technology allows for sustained local drug delivery, potentially improving treatment efficacy while reducing systemic exposure—a significant advantage in bladder cancer therapies.
Wall Street remains broadly bullish on the stock, with seven of eight analysts rating it a "Buy" and a consensus price target of $35.25, according to MarketBeat data. The shares closed at $21.70 on Friday, giving the company a market capitalization of approximately $1.02 billion.
Looking ahead, investors will be focused on the trajectory of ZUSDURI adoption following the J Code implementation and progress toward the UGN-103 NDA submission. The company projected operating expenses of $240 million to $250 million for 2026, including $20 million to $24 million in non-cash share-based compensation.
UroGen's pipeline also includes UGN-102, currently in a Phase 3 trial for low-grade intermediate-risk non-muscle invasive bladder cancer, providing additional potential long-term catalysts beyond the current commercial products.